Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Madrigal Pharmaceuticals, Inc. (MDGL)

430.36 -1.34 (-0.31%)
At close: 4:00:01 PM EDT
430.36 0.00 (0.00%)
After hours: 4:00:13 PM EDT
Trade MDGL on Coinbase
Chart Range Bar
Loading chart for MDGL
  • Previous Close 431.70
  • Open 431.55
  • Bid 466.11 x 100
  • Ask 466.29 x 100
  • Day's Range 424.99 - 437.80
  • 52 Week Range 399.00 - 615.00
  • Volume 251,449
  • Avg. Volume 278,496
  • Market Cap (intraday) 9.943B
  • Beta (5Y Monthly) -1.05
  • PE Ratio (TTM) --
  • EPS (TTM) -12.85
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 685.22
  • Zacks Rating Neutral

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

www.madrigalpharma.com

915

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MDGL
26.10%
S&P 500 (^GSPC)
10.73%

1-Year Return

MDGL
0.66%
S&P 500 (^GSPC)
11.11%

3-Year Return

MDGL
241.15%
S&P 500 (^GSPC)
81.91%

5-Year Return

MDGL
453.52%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 364.25M
Earnings -57.94M
Profit Margin -15.91%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-100M
0
100M
200M
300M
-35.0%
-30.0%
-25.0%
-20.0%

Analyst Insights

View More

Analyst Price Targets

533.00
685.22 Average
430.36 Current
962.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/23/2026
Analyst Citigroup
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 725

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -25.32%

  • Return on Assets (ttm)

    -17.84%

  • Return on Equity (ttm)

    -53.31%

  • Revenue (ttm)

    1.28B

  • Net Income Avi to Common (ttm)

    -325.1M

  • Diluted EPS (ttm)

    -12.85

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    838.75M

  • Total Debt/Equity (mrq)

    66.40%

  • Levered Free Cash Flow (ttm)

    -80.47M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: